Comparative Pharmacology
Head-to-head clinical analysis: ACCRUFER versus PROFERDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCRUFER versus PROFERDEX.
ACCRUFER vs PROFERDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACCRUFER (ferric maltol) is an oral iron replacement therapy. Ferric iron is complexed with maltol, which enhances absorption. Once absorbed, iron is utilized for hemoglobin synthesis and erythropoiesis.
PROFERDEX (iron dextran) is a colloidal solution of ferric hydroxide in complex with dextran, providing a source of iron for hemoglobin synthesis and erythropoiesis. Iron is incorporated into heme, which is essential for oxygen transport in red blood cells.
170 mg (1 tablet) orally twice daily (340 mg total daily dose) for adults with iron deficiency anemia, taken on an empty stomach at least 1 hour before or 2 hours after meals.
100 mg intramuscular or intravenous every 3 to 7 days; may increase to 200 mg per dose.
None Documented
None Documented
20 hours (prolonged in hepatic impairment)
Terminal half-life approximately 20-30 hours in patients with normal hepatic function; prolonged in hepatic impairment. Clinical context: supports every-3-week dosing.
Renal 65% (as unchanged drug), fecal 35%
Primarily fecal (biliary excretion of iron from degraded RBCs, about 80-90%); renal excretion negligible (<5% unchanged).
Category C
Category C
Iron Replacement
Iron Replacement